Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- 7-[[4-[(3-ethynylphenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-hydroxy-heptanamide
- Correlated keywords
- inhibitors histones deacetylases cancers receptors biochemistry proteins kinases apoptosis epigenetics signals transductions intracellular signaling biochemicals 1012060-66-0 CUDC 101 CUDC101 multitargets multi-targets targets multi combines functional groups potent humans epidermal growths factors HERs HDACs blocks tyrosines EGFRs HER1s HER2 HER-1 HERs ones twos HER-2 2s 1s inhibits classes I II activities activity prevents preventions cells in vitro slows tumors induces inducing regressions xenografts models acquired resistances single-targets singletargets singles blocks blocked blocking proliferations proliferating proliferates reduces migrations
- Product Overview:
CUDC-101 is a multi-target inhibitor, combining functional groups of potent inhibitors of human epidermal growth factor receptor (HER) kinases and histone deacetylases (HDACs). It potently blocks the receptor tyrosine kinases EGFR (aka HER1) and HER2 (IC50s = 2.4 and 16.4 nM, respectively).{26830} CUDC-101 also inhibits the activity of class I and class II HDACs at nanomolar concentrations (e.g., IC50s = 4.5, 12.6, 13.2, and 11.4 nM for HDAC1, 2, 4, and 5, respectively).{26830} It has only weak effects on over 60 other kinases when tested at 5 µM.{26830} CUDC-101 prevents the growth of a wide range of cancer cell lines in vitro, and slows tumor growth or induces tumor regression through cancer cell apoptosis in xenograft models.{26830} In cancer cells that have acquired resistance to single-target EGFR inhibitors, CUDC-101 blocks proliferation and reduces cell migration.{26829}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.